2. Signaling Pathways
  3. Epigenetics
  4. Epigenetic Reader Domain
  5. Brd Isoform

Brd

BRD4 (Bromodomain-containing protein 4) is a member of the BET (bromodomain and extra-terminal) family of epigenetic reader proteins that recognize acetylated lysine residues on histones and transcription-associated proteins through tandem bromodomains, thereby linking chromatin acetylation to transcriptional regulation and gene expression programs[1][2]. BRD4 functions as a chromatin-associated transcriptional regulator and remains associated with chromatin during mitosis, supporting the maintenance of transcriptional states across cell divisions[3][4]. Mechanistically, BRD4 promotes transcriptional elongation through interactions with transcriptional machinery and contributes to the activation of genes involved in cell-cycle progression, proliferation, and oncogenic signaling pathways[2][5]. Dysregulated BRD4 activity has been implicated in multiple cancers, including hematologic malignancies and NUT carcinoma, where BRD4-dependent transcriptional programs support tumor growth and survival[2][6]. Compared with related BET family members, BRD4 contains a distinctive C-terminal region that is absent or less developed in BRD2 and BRD3, providing functional specialization beyond the shared bromodomain-mediated recognition of acetylated chromatin[7][8]. Although BET proteins exhibit conserved bromodomains, genetic and pharmacological studies indicate non-redundant biological functions among BRD2, BRD3, and BRD4, supporting isoform-specific investigation in disease models[3][9]. For experimental applications, small-molecule BET inhibitors such as JQ1 competitively block BET bromodomains, displace BRD4 from chromatin-associated targets, and have become widely used chemical probes for dissecting epigenetic transcriptional regulation and evaluating therapeutic vulnerabilities in cancer models[2][10].

Brd Related Products (4):

Cat. No. Product Name Effect Purity
  • HY-101125
    L-Moses
    		Inhibitor 99.97%
    L-Moses (L-45), a chemical probe, is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM.
  • HY-101125A
    L-Moses dihydrochloride
    		Inhibitor 99.38%
    L-Moses (L-45) dihydrochloride is the first potent, selective, and cell-active p300/CBP-associated factor (PCAF) bromodomain (Brd) inhibitor with a Kd of 126 nM.
  • HY-128703
    Bromodomain inhibitor-8
    		Inhibitor 98.02%
    Bromodomain inhibitor-8 (example 1) is a BET bromodomain inhibitor for treating autoimmune and inflammatory diseases.
  • HY-161889
    DCSM06-05
    		Inhibitor
    DCSM06-05 is a potent SMARCA2-BRD inhibitor with an IC50 value of 9 µM, a Kd value of 22.4 µM.